Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a gastrointestinal syndrome that causes chronic abdominal pain and variable bowel habits associated with defecation without an organic pathology and that does not threaten life but disrupts the quality of life. Chronic and recurrent abdominal pain and variable bowel habits (constipation, diarrhea or both) are the main clinical features of IBS. ROMA IV diagnostic criteria is used for diagnosis. If the diagnostic criteria are fully met and there is no alarm symptom IBS can be diagnosed without the need for a diagnostic test. 70% of IBS patients have mild symptoms and do not refer to any health institution. In the remaining 30% of the patients symptoms are mode-rate to severe,with the majority being treated in primary care. IBS is a high-cost disease because of unsatisfactory results in relieving the symptoms, unnecessary examinations / treatments, consultation / operation and which leads to an increase in health expenditures and loss of labor. The most important step in the treatment is the strict patient-physician relationship.IBS, which is one of the most common diseases in primary health care, is easily diagnosed, treated and followed-up. The use of ROMA IV diagnostic criteria in daily practice is necessary for standardization and accurate diagnosis. The biopsychosocial evaluation of the patient in accordance with the principles of holistic and comprehensive approach of family medicine is important in controlling the disease.
References
- Wald A, Talley NJ, Grover S. Clinical manifestations and diagnosis of irritable bowel syndrome in adults. http://0210cgyzn.y.https.www.uptodate.com.proxy2.marmara-elibrary.com/contents/clinical-manifestations-and-diagnosis-of-irritable-bowel-syndrome-in-adults?
- Özlem M, Perktaş G. İrritabl bağırsak sendromunda diyet. Güncel Gastroenteroloji Dergisi 2016;20(3):274-9.
- Cumming, W. Electro-galvanism in a peculiar affliction of the mucous membrane of the bowels. London Medical Gazette 1849;9:969–73.
- Osler W. The principles and practice of medicine. New York, Appleton & Co, 1892.
- Wilson S. et al. Prevalance of irritable bowel syndrome:a community survey. Br J Gen Pract 2004:54(504):495-502.
- Drossman DA, Chang L, Chey WD, Kellow J, Tack J, Whitehead WE. and Rome IV Committees. Rome IV Functional Gastrointestinal Disorders For Primary Care And Non -GI Clinicians, First Edition. Raleigh NC, Rome Foundation Inc, 2016.
- Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-21.
- Celebi S, Acik Y, Deveci SE, et al. Epidemiological features of irritable bowel syndrome in a Turkish urban society. J Gastroenterol Hepatol 2004;19:738-43.
- Yilmaz S, Dursun M, Ertem M, Canoruc F, Turhanoğlu A. The epidemiological aspects of irritable bowel syndrome in Southeastern Anatolia: a stratified randomised community-based study. Int J Clin Pract 2005;59:361-9.
- Özden A, Köksal ŞA, Oğuz D, Çiçek B, Yılmaz U, Dağlı Ü. Türkiye’de birinci basamak sağlık kurumlarında irritabl bağırsak sendromu görülme sıklığı. Akademik Gastroenteroloji Dergisi 2006; 5 (1): 4-15.
- Özgen K, Şahin EM, Uludağ A, Peker E, Günayi Z, Ertekin YH. Birinci basamakta irritabl barsak sendromu prevalansı. Cukurova Med J 2017;42(2):216-22.
- Kaya M, Kaçmaz H. Roma IV kriterlerine göre fonksiyonel bağırsak hastalıklarının yeniden değerlendirilmesi. Güncel Gastroenteroloji Dergisi 2016,20(4):393-407.
- Drossman DA, Chang L, Chey WD, Kellow J, Tack J, Whitehead WE. Diagnostic Questionnaires and Tables for Investigators and Clinicians. First Edition. Raleigh NC, Rome Foundation Inc, 2016.
- Lee OY, Mayer EA, Schmulson M, et al: Gender-related differences in İBS symptoms. Am J Gastroenterol 2001; 96:2184-93.
- Bennet G, Talley NJ. Irritable bowel syndrome in the elderly. Best practice & Research Clinical Gastoenterology 2002;16(1):63-76.
- Inadomi JM, Fennerty MB, Bjorkman D. The economic impact of irritabl bowel syndrome. Aliment Pharmacol Ther 2003;18(7):671–82.
- Longstreth GF. et al. Irritable bowel syndrome, health care use, and costs: A U.S. Managed care perspective. The American Journal of Gastroenterology 2003;98 (3):601-7.
- Can G, Yılmaz B. İrritabl bağırsak sendromunun tanı ve tedavisinde yaklaşımlar. Güncel Gastroenteroloji Dergisi 2015,19(3):181-91.
- Lacy BE. et al. Bowel disorders. Gastroenterology 2016;150:1394-407.
- Mayer EA, Tillisch K, Bradesi S. Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Aliment Pharmacol Ther 2006; 24: 919-33.
- Beesley H, Rhodes J, Salmon P. Anger and childhood sexual abuse are independently associated with irritable bowel syndrome. Br J Health Psychol 2010; 15: 389–99.
- Moldofsky H. Sleep and pain. Sleep Medicine Reviews 2001;5(5):387–98.
- Blanchard EB, Lackner JM, Jaccard J, et al. The role of stress in symptom exacerbation among IBS patients. J Psychosom Res 2008; 64: 119–28.
- Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil 2017;23(2):151-63.
- Fukudo S. et al. Evidence based clinical practice guidelines for irritable bowel syndrome. J Gastoenterol 2015; 50:11-30. doi:10.1007/s005335-014-1017-0
- Özdemir M, Perktaş G. İrritable bağırsak sendromunda diyet. Güncel Gastroenteroloji 2016;(20)4:274-9.
- Akbulut G, Çiftçi H, Yıldız E. Sindirim sistemi hastalıkları ve beslenme tedavisi. Ankara, Sağlık Bakanlığı Yayını No:728, 2008.
- Coşkun T. Pro-pre ve simbiyotikler. Çocuk Sağlığı ve Hastalıkları Dergisi 2006;49:128-48.
- Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.
- Maagaard, L. et al. Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet. World Journal of Gastroenterology 2016;22(15): 4009.
- Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: A systematic review and meta-analysis. Am J Gastroenterol 2014;109:1367-74.
- Chapman RW, Stanghellini V, Geraint M, et al. Randomized clinical trial: Macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013; 108: 1508–15.
- Akyüz F. İrritable bağırsak sendromu. Güncel Gastroenteroloji 2016;20(4):415-20.
- Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702–12.
- Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714–24; quiz 1725.
- Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: Lubiprostone in patients with constipation associated irritable bowel syndrome – results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329–41.
- Khan S, Chang L. Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol 2010;7:565-81.
- Battaglia G, Morselli-Labate AM, Camarri E, et al. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther 1998;12:1003-10.
- Clave P, Acalovschi M, Triantafillidis JK, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2011;34:432-42.
- Triantafillidis JK, Malgarinos G. Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review. Clin Exp Gastroenterol 2014;7:75-82.
- Comar KM, Kirby DF: Herbal remedies in gastroenterology. J Clin Gastroenterol 2005; 39:457-68.
- Tillisch K: Complementary and Alternative Medicine for Gastrointestinal Disorders. Clin Med 2007; 7:224-7.
- Langmead L, Chitnis M, Rampton DS. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis 2002;8:174–9.
- Kligler B, Chaudhary S. Peppermint oil. Am Fam Physician 2007;75(7):1027–30.
- Ford AC, Talley NJ, Spiegel BMR, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of Irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:2313.
- Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 2014;48(6):505–12.
- Madisch A, Holtmann G, Plein K, et al. Treatment of Irritable bowel syndrome with herbal preparations: Results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004;19:271–9.
- Melzer J, Rosch W, Reichling J, et al. Meta-analysis: Phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004;20:1279–87.
- Bannerman RH. Acupuncture, the WHO view: China. 1979 December 1979:27-28.
- Tunç N, Yalnız M. Komplementer tedavinin fonksiyonel gastrointestinal sistem hastalıklarında yeri. Güncel Gastroenteroloji 2017;21(4):345-52.
- Palsson OS, Whitehead WE. Psychological treatments in functional gastrointestinal disorders. Clin Gastroenterol Hepatol 2013;11(3):208-16.
- Payne A, Blanchard EB. A controlled comparison of cognitive therapy and selfhelp support groups in the treatment of Irritable bowel syndrome. J Consult Clin Psychol 1995;63:779–86.
- Webb AN, Kukuruzovic RH, Catto-Smith AG, Sawyer SM. Hypnotherapy for treatment of Irritable bowel syndrome. Cochrane Database Syst Rev 2007;17(4):CD005110.
- Gonsalkorale WM, Miller V, Afzal A, et al. Long term benefits of hypnotherapy for Irritable bowel syndrome. Gut 2003;52:1623–9.